Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection
Status:
Terminated
Trial end date:
2018-07-11
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to 1) evaluate the safety of a series of injections
with the AGS-004 product in combination with a series of Vorinostat doses and 2) to help
scientists evaluate ways of reactivating latent (non-acting) HIV virus and determine if the
immune system can be made stronger to eliminate the activated HIV virus.
Phase:
Phase 1
Details
Lead Sponsor:
Cynthia L Gay, MD University of North Carolina, Chapel Hill
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)